Adding Venetoclax to BTKi

[antonb]

What about patients having been stable on BTK inhibitorsi for years? Would they be eligible to add Venetoclax, now that the combination is approved by FDA?

Taking in mind that they have normal labs, there is no risk of tumor Lysis Syndrome caused by Venetoclax and could switch life treatments, for fixed ones and be able to achieve uMRD

Any ideas ?

[hhk50]

You are describing my situation, although I decided not to add the Venetoclax. My cancer doc is an advocate of I&V. I have been on Ibrutinib for five years - good numbers and minimal problems. He offered to add Venetoclax with the idea of achieving UMRD in around a year. I decided against it. Why? The old saying goes, "don't mess with success."

[antonb in reply to hhk50]

Who is your Dr ? where are you treated ?

[hhk50 in reply to antonb]

Hello Anton - I am being treated at the University of Kansa Medical Center located in Kansas City, KS. If you are anywhere close, and want to talk to them, just send me a PM and I will pass along contact info.

[Skyshark]

For your markers of uIgHV + TP53 aberration, I+V for treatment naive (TN) has reached median at 49 months from start of treatment. That's 3 years drug free to progression and maybe a year more to start of next treatment.

V+O is 47 months to median for those markers but it's 11 months treatment instead of 13.8 so a month longer drug free.

No one has tested a change of protocol in the middle of treatment. They always test TN and relapsed/refractory separately.

The median time is short compared to other markers, it's time out during which you won't develop resistance to BTKi drugs. Although that risk remains during the 12 months on V+I.